Article successfully added.

CyFlow™ CD23 FITC

CyFlow™ CD23 FITC
Alternative Name: BLAST-2, FcɛRII
Antibody: Yes
Antigen: CD23
Application: Flow cytometry
Clonality: monoclonal
Clone: EBVCS-5
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Field of Interest: Immunophenotyping
Format/Fluorochrome: FITC
Isotype: IgG1
Laser: Blue
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: CS137840

For Research Use Only

Build Your Own Reagent Panel
Quantity 100 tests Volume 0.4 mL Immunogen EBV-transformed human cells Background... more
CyFlow™ CD23 FITC
Quantity100 tests
Volume0.4 mL
ImmunogenEBV-transformed human cells
Background InformationCD23 (FcεRII, BLAST-2), the low affinity IgE receptor, is a 45 kDa type II membrane glycoprotein expressed on eosinophils, follicular dendritic cells, Langerhans cells, mature B cells (mainly upon activation), EBV-transformed lymphoblasts, monocytes, and subpopulation of platelets. CD23 mediates IgE-dependent cytotoxicity by eosinophils and macrophages, and downregulates IgE secretion in response to high levels of IgE, involving release of pro-inflammatory cytokines.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Ling NR, Stevenson FK, Brown B: Urinary excretion of CD23 antigen in normal individuals and patients with chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1991 Dec; 86(3):360‑6. < PMID: 1721010 > | Yamaoka KA, Arock M, Issaly F, Dugas N, Le Goff L, Kolb JP: Granulocyte macrophage colony stimulating factor induces Fc epsilon RII/CD23 expression on normal human polymorphonuclear neutrophils. Int Immunol. 1996 Apr; 8(4):479‑90. < PMID: 8722638 > | Rumi C, Rutella S, Leone G, Bonini S: Fc‑RII/CD23 receptor on circulating human eosinophils. Blood. 1998 Apr 1; 91(7):2621‑2. < PMID: 9516167 > | Belleau JT, Gandhi RK, McPherson HM, Lew DB: Research upregulation of CD23 (FcepsilonRII) expression in human airway smooth muscle cells (huASMC) in response to IL‑4, GM‑CSF, and IL‑4/GM‑CSF. Clin Mol Allergy. 2005 May 20; 3:6. < PMID: 15907205 > | Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S: Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1; 13(15‑1):4448‑55. < PMID: 17671129 >